

ALLERGAN INC
Form 4
February 13, 2014

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
LAVIGNE LOUIS J JR

(Last) (First) (Middle)
2525 DUPONT DRIVE
(Street)
IRVINE, CA 92612
(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ALLERGAN INC [AGN]

3. Date of Earliest Transaction
(Month/Day/Year)
02/11/2014

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership: Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|--|
| | | | Code | V | Amount (A) or (D) Price | | |
| Common Stock | 02/11/2014 | | M | | 11,400 A \$ 54.32 | 24,123 | D |
| Common Stock | 02/11/2014 | | S | | 11,400 D \$ 122.41 (1) | 12,723 | D |
| Common Stock | 02/11/2014 | | M | | 11,400 A \$ 46.66 | 24,123 | D |
| Common Stock | 02/11/2014 | | S | | 11,400 D \$ 122.41 (2) | 12,723 | D |
| Common Stock | 02/11/2014 | | M | | 11,400 A \$ 61.98 | 24,123 | D |
| Common Stock | 02/11/2014 | | S | | 11,400 D \$ 122.4 | 12,723 | D |

Edgar Filing: ALLERGAN INC - Form 4

| | | | | | | | | | |
|--------------|------------|--|---|--------|---|----------------------|--------|---|--|
| Common Stock | | | | | | | | | |
| Common Stock | 02/11/2014 | | M | 9,000 | A | \$ 51.715 | 21,723 | D | |
| Common Stock | 02/11/2014 | | S | 9,000 | D | \$ 122.401 (3) | 12,723 | D | |
| Common Stock | 02/11/2014 | | M | 11,400 | A | \$ 60.6 | 24,123 | D | |
| Common Stock | 02/11/2014 | | S | 11,400 | D | \$ 122.349 (4) | 12,723 | D | |
| Common Stock | | | | | | | 4,800 | I | By Lavigne Survivor's Trust (5) |
| Common Stock | | | | | | | 5,400 | I | By Rachel Lavigne Exmpt Bypass Trust (6) |
| Common Stock | | | | | | | 0 | I | By Lavigne Family Trust (7) |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Security (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|
| | | 02/11/2014 | | M | 11,400 | (9) 05/06/2018 | |

| | | | | | | | | | | |
|--|------------------------|------------|---|--------|-------------|------------|--|--|--------------|-----|
| Nonemployee Director Stock Option (Right to Buy) | \$ 54.32 <u>(8)</u> | | | | | | | | Common Stock | |
| Nonemployee Director Stock Option (Right to Buy) | \$ 46.66 | 02/11/2014 | M | 11,400 | <u>(9)</u> | 04/30/2019 | | | Common Stock | 11, |
| Nonemployee Director Stock Option (Right to Buy) | \$ 61.98 | 02/11/2014 | M | 11,400 | <u>(9)</u> | 04/29/2020 | | | Common Stock | 11, |
| Nonemployee Director Stock Option (Right to Buy) | \$ 51.71 | 02/11/2014 | M | 9,000 | 05/02/2007 | 05/02/2016 | | | Common Stock | 9, |
| Nonemployee Director Stock Option (Right to Buy) | \$ 60.6 | 02/11/2014 | M | 11,400 | <u>(10)</u> | 05/01/2017 | | | Common Stock | 11, |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| LAVIGNE LOUIS J JR 2525 DUPONT DRIVE IRVINE, CA 92612 | X | | | |

Signatures

/s/ Matthew J. Maletta, Attorney-In-Fact for Louis J. Lavigne, Jr.

02/12/2014

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The price reported in column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from \$122.40 to \$122.457, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities Exchange Commission, upon request, the full information regarding the number of shares sold at each price within the range set forth in this footnote.

(2) The price reported in column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from \$122.40 to \$122.54, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities Exchange Commission, upon request, the full information regarding the number of shares sold at each price within the range set forth in this footnote.

(3) The price reported in column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from \$122.37 to \$122.43, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the

Edgar Filing: ALLERGAN INC - Form 4

staff of the Securities Exchange Commission, upon request, the full information regarding the number of shares sold at each price within the range set forth in this footnote.

- (4) The price reported in column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from \$122.32 to \$122.494, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities Exchange Commission, upon request, the full information regarding the number of shares sold at each price within the range set forth in this footnote.
- (5) Shares held by the Louis Lavigne Survivor's Trust. Reporting Person is sole trustee of the Louis Lavigne Survivor's Trust.
- (6) Shares held by the Rachel Lavigne Exmpt Bypass Trust. Reporting Person is sole trustee of the Rachel Lavigne Exmpt Bypass Trust.
- (7) Shares held by the Lavigne Family Trust. Reporting Person is trustee of the Lavigne Family Trust.
- (8) The per share exercise price is the closing price of Allergan's common stock as of the date of grant.
- (9) Option is fully vested and exercisable upon the earlier to occur (i) the first anniversary of the grant date, or (ii) the annual meeting held during such calendar year at which one or more members of the board are standing for re-election following the date of grant.
- (10) Option is fully vested and exercisable on the date of the next regular annual meeting of stockholders of Allergan, Inc. at which directors are to be elected following the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.